Spironolactone inhibits podocyte motility via decreasing integrin β1 and increasing integrin β3 in podocytes under high-glucose conditions

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6849-6854

  Li, Zhuo ^a,b   Zhang, Li ^b   Shi, Wei ^b   Chen, Yuanhan ^b   Zhang, Hong ^b   Liu, Shuangxin ^b   Liang, Xinling ^b   Ling, Ting ^b   Yu, Chunping ^b   Huang, Zhongshun ^a,b   Tan, Xiaofan ^a,b   Zhao, Xinchen ^a,b   Ye, Zhiming ^b   Zhang, Bin ^b   Wang, Wenjian ^b   Li, Ruizhao ^b   Ma, Jianchao ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Integrin 1; Integrin 3; Podocyte; Spironolactone

Indexed keywords

BETA1 INTEGRIN; BETA3 INTEGRIN; GLUCOSE; SPIRONOLACTONE;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DIABETES MELLITUS; IMMUNOFLUORESCENCE; IN VITRO STUDY; MOUSE; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL MOTION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD29; CELL LINE; CELL MOVEMENT; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLUCOSE; INTEGRIN BETA3; MICE; PODOCYTES; SPIRONOLACTONE;

EID: 84943609141     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4295     Document Type: Article

References (37)

1. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH and Steffes MW; American Diabetes Association. Nephropathy in diabetes. Diabetes Care 27 (Suppl 1): S79-S83, 2004.
2. Ritz E, Rychlik I, Locatelli F and Halimi S: End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 34: 795-808, 1999.
3. Wolf G, Chen S and Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634, 2005.
4. Li JJ, Kwak SJ, Jung DS, Kim JJ, Yoo TH, Ryu DR, Han SH, Choi HY, Lee JE, Moon SJ, et al: Podocyte biology in diabetic nephropathy. Kidney Int Suppl S36-S42, 2007.
5. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L and Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997.
6. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, De Cosmo S and Viberti G: Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 51: 3083-3089, 2002.
7. D'Agati VD: Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts). Kidney Int 73: 399-406, 2008.
8. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Hozman LB and Wiggins RC: Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16: 2941-2952, 2005.
9. Wu X, Wang J, Jiang H, Hu Q, Chen J, Zhang J, Zhu R, Liu W and Li B: Wnt3a activates 1-integrin and regulates migration and adhesion of vascular smooth muscle cells. Mol Med Rep 9: 1159-1164, 2014.
10. Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R and Geiger B: Functional atlas of the integrin adhesome. Nat Cell Biol 9: 858-867, 2007.
11. Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B and Tsilibary EC: Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 284: F671-F679, 2003.
12. Fassler R and Meyer M: Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev 9: 1896-1908, 1995.
13. Kanasaki K, Kanda Y, Palmsten K, Tanjore H, Lee SB, Lebleu VS and Gattone VH Jr and Kalluri R: Integrin beta1-mediated matrix assembly and signaling are critical for the normal development and function of the kidney glomerulus. Dev Biol 313: 584-593, 2008.
14. Pozzi A, Jarad G, Moeckel GW, Coffa S, Zhang X, Gewin L, Eremina V, Hudson BG, Borza B, Harris RC, et al: Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity. De Biol 316: 288-301, 2008.
15. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, et al: Modification of kidney barrier function by the urokinase receptor. Nat Med 14: 55-63, 2008.
16. Sachs N and Sonnenberg A: Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol 9: 200-210, 2013.
17. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, et al: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952-960, 2011.
18. Cha DR, Kang YS, Han SY, Jee YH, Han KH, Kim HK, Han JY and Kim YS: Role of aldosterone in diabetic nephropathy. Nephrology (Carlton) 10 (Suppl): S37-S39, 2005.
19. Shibata S, Nagase M, Yoshida S, Kawachi H and Fujita T: Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1. Hypertension 49: 355-364, 2007.
20. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P and Parving HH: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70: 536-542, 2006.
21. Aguilar C and Rodriguez-Delfin L: Effects of spironolactone administration on the podocytes loss and progression of experimental diabetic nephropathy. Rev Peru Med Exp Salud Publica 29: 490-497, 2012 (In Spanish).
22. Lin S, Li D, Jia J, Zheng Z, Jia Z and Shang W: Spironolactone ameliorates podocytic adhesive capacity via restoring integrin alpha 3 expression in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 11: 149-157, 2010.
23. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W and Zeller R: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236: 248-258, 1997.
24. Zhang B, Xie S, Shi W and Yang Y: Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 27: 1746-1755, 2012.
25. Weil EJ, Lemley KV, Yee B, Lovato T, Richardson M, Myers BD and Nelson RG: Podocyte detachment in type 2 diabetic nephropathy. Am J Nephrol 33 (Suppl 1): 21-24, 2011.
26. Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, Michael AF, Fan WW, Zhou B and Tsilibary EC: Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 284: F671-F679, 2003.
27. Zhang L, Li R, Shi W, Liang X, Liu S, Ye Z, Yu C, Chen Y, Zhang B, Wang W, et al: NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice. Br J Pharmacol 170: 426-439, 2013.
28. Borza CM, Pozzi A, Borza DB, Pedchenko V, Hellmark T, Hudson BG and Zent R. Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant inhibitor forintegrin alphavbeta3. J Biol Chem 281: 20932-20939, 2006.
29. Nagase M and Fujita T: Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 12: 233-242, 2008.
30. Siragy HM and Xue C: Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol 93: 817-824, 2008.
31. Lee SH, Yoo TH, Nam BY, Kim DK, Li JJ, Jung DS, Kwak SJ, Ryu DR, Han SH, Lee JE, et al: Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 297: F1381-F1390, 2009.
32. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, et al: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362-1372, 2006.
33. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K and Iida M: Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 26: 2475-2484, 2011.
34. Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M and Nakata T: Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol 589: 264-271, 2008.
35. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS and Cha DR: Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70: 111-120, 2006.
36. Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, Shjoedt KJ, Parving HH and Rossing P: Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: A randomized placebo-controlled crossover study. Diabet Med 29: e184-e190, 2012.
37. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F and Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 28: 2106-2112, 2005.